Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections

Highlights

- A Powassan virus LNP-mRNA vaccine induces potently neutralizing antibodies in mice
- One dose of the mRNA vaccine protects against lethal Powassan virus challenge
- The antibody response to the vaccine neutralizes other tick-borne flaviviruses
- The vaccine cross-protects against disease following challenge with Langat virus

In Brief

VanBlargan et al. demonstrate a lipid nanoparticle-encapsulated mRNA vaccine against Powassan virus, an emerging tick-borne flavivirus, is highly immunogenic in mice and protects against lethal Powassan virus infection. Furthermore, the vaccine induces a cross-reactive antibody response against other tick-borne flavivirus that is protective against disease caused by Langat virus infection in mice.
An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections

Laura A. VanBlargan, Sunny Himansu, Bryant M. Foreman, Gregory D. Ebel, Theodore C. Pierson, and Michael S. Diamond

1Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
2Moderna, Inc., 500 Technology Square, Cambridge, MA 02139, USA
3Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
4Arthropod-Borne and Infectious Diseases Laboratory, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA
5Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
6Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA
7The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA
8Lead Contact
*Correspondence: diamond@wusm.wustl.edu
https://doi.org/10.1016/j.celrep.2018.11.082

SUMMARY

Powassan virus (POWV) is an emerging tick-transmitted flavivirus that circulates in North America and Russia. Up to 5% of deer ticks now test positive for POWV in certain regions of the northern United States. Although POWV infections cause life-threatening encephalitis, there is no vaccine or countermeasure available for prevention or treatment. Here, we developed a lipid nanoparticle (LNP)-encapsulated modified mRNA vaccine encoding the POWV prM and E genes and demonstrated its immunogenicity and efficacy in mice following immunization with one or two doses. The POWV mRNA vaccine induced high titers of neutralizing antibody and sterilizing immunity against lethal challenge with different POWV strains. The mRNA vaccine also induced cross-neutralizing antibodies against multiple other tick-borne flaviviruses and protected mice against the distantly related Langat virus. These data demonstrate the utility of the LNP-mRNA vaccine platform for the development of vaccines with protective activity against multiple flaviviruses.

INTRODUCTION

Powassan virus (POWV) is a tick-borne flavivirus (TBFV) that was first described following its isolation from the brain of a child who died of encephalitis in Powassan, Ontario, in 1958 (McLean and Donohue, 1959). Human cases of POWV have been reported in the United States, Canada, and Russia (reviewed in Ebel, 2010; Hermance and Thangamani, 2017). Though POWV infections are relatively rare, they can cause severe or even fatal neuroinvasive disease, including encephalitis, meningoencephalitis, and meningitis. Approximately 10% of neuroinvasive POWV cases are fatal, and 50% of survivors suffer long-term neurological sequelae (Ebel, 2010; Hermance and Thangamani, 2017). Unfortunately, POWV is emerging; increasing numbers of cases have been diagnosed in the United States over the past decade (Hermance and Thangamani, 2017; McLean and Donohue, 1959). Human cases of POWV have been reported in the United States, Canada, and Russia (Aliota et al., 2014; Anderson and Armstrong, 2012; Knox et al., 2017).

Two genetic lineages of POWV circulate in North America, lineage I and lineage II (also called deer-tick virus [DTV]), although they are serologically and clinically indistinguishable and share at least 96% amino acid identity in their envelope (E) proteins (Ebel et al., 2001). POWV lineage I strains are predominantly maintained in Ixodes cookei ticks and include isolates from New York and Canada, whereas lineage II strains are found in Ixodes scapularis deer ticks and include strains from regions infested by these ticks (Ebel et al., 2001). Because deer ticks are more aggressive at biting humans, lineage II viruses may have greater epidemic potential. Although POWV has been found predominantly in north-central and northeastern parts of the United States in Ixodes species ticks, POWV also has been isolated from Dermacentor andersoni ticks in Colorado (Thomas et al., 1960), indicating the vector and geographical range may be larger than previously estimated.

The TBFVs are divided into three groups: the mammalian group, the seabird group, and the Kadam virus group (Grard et al., 2007). The mammalian TBFV group includes POWV and several other human pathogens, including tick-borne encephalitis virus (TBEV), Omsk hemorrhagic fever virus (OHFV), Kyasanur forest disease virus (KFDV), and Alkhurma hemorrhagic fever virus (AHFV). Within their E proteins, the mammalian TBFV group shares ≥70% amino acid identity but only about 54%–60% identity with seabird TBFVs. One exception is Gadgets Gully virus (GGYV), which is more closely related to the mammalian TBFVs even though it causes infection of seabirds (Grard et al., 2007). Vaccines have been developed against several mammalian TBFVs, although only TBEV vaccines have proven efficacy (Shikawa et al., 2014). TBEV vaccines induce antibodies capable of neutralizing closely related TBFVs, including OHFV, KFDV, and AHFV (McAuley et al., 2017). However, TBEV immune sera...
had limited cross-neutralizing activity against the more distantly related POWV. No approved vaccines for POWV exist. The lack of a POWV-specific vaccine, limited induction of cross-neutralizing antibodies by other TBFV vaccines, and epidemic potential for POWV prompted us to design a vaccine and test its immunogenicity and efficacy. We selected a vaccine platform that we developed for a distantly related flavivirus, Zika virus (ZIKV): a lipid nanoparticle (LNP)-encapsulated modified mRNA encoding the structural premembrane (prM) and E protein genes (Richner et al., 2017a). Co-expression of the flavivirus structural proteins prM and E results in the secretion of subviral particles (SVPs) that share many functional and antigenic features with infectious virions and elicit neutralizing antibodies. SVPs are heterogeneous in size and likely display E proteins in distinct chemical environments, with the potential to affect epitope display (Allison et al., 1995; Heinz et al., 1995; Kiermayr et al., 2009; Konishi and Fujii, 2002; Konishi et al., 1992). In addition to selecting the POWV prM-E structural gene components, we used an mRNA platform, because some modified mRNA have been reported to enhance follicular helper T cell and germinal center B cell responses that are essential for inducing memory B cells and durable levels of neutralizing antibody (Pardi et al., 2018).

Here, we describe an LNP-encapsulated modified mRNA vaccine encoding the prM-E of POWV that induces a potent neutralizing antibody response in mice and protects against lethal viral challenge by strains of both POWV lineages. Furthermore, the POWV mRNA vaccine induced cross-neutralization antibody titers against other TBFVs and conferred protection against disease following challenge of mice with the distantly related Langat virus (LGTV).

RESULTS

A Lethal Model of POWV Infection in Adult Mice

In planning for vaccine efficacy studies, we developed challenge models of POWV infection in adult mice. Although others have described murine models of POWV infection, these have been in juvenile mice (4–5 weeks old), which are not ideal for experiments requiring iterative immunization and resting periods (Hermance and Thangamani, 2015; Holbrook et al., 2005; Mlera et al., 2017; Santos et al., 2016; Wang et al., 2013). Accordingly, we tested the ability of two POWV strains, LB (a lineage I strain) and Spooner (a lineage II DTV strain) to cause morbidity and mortality in wild-type (WT) C57BL/6 mice at 7 or 14 weeks of age. Following subcutaneous inoculation of 10^2 focus-forming units (FFU) of POWV LB, lethal infection ensued in 93% of 7- and 14-week-old mice, with a mean time to death of 8.6 and 9.5 days post-infection (dpi), respectively (Figure 1A). All mice inoculated with POWV LB lost approximately 15%–25% of their body weight (Figure 1B). POWV LB-infected mice exhibited ruffled fur, hunched posture, lethargy, and partial paralysis,
although ~50% of mice did not exhibit these signs before death (Figure 1C). In comparison, POWV Spooner resulted in lower mortality rates; 57% and 60% of 7- and 14-week-old mice succumbed to infection with mean times to death of 13.0 and 12.7 days, respectively (Figure 1D). Because of the partial lethality caused by POWV Spooner in WT mice, we created a more susceptible host by transiently blocking type I interferon (IFN) signaling with an anti-IFN receptor (Ifnar1) monoclonal antibody (mAb), MAR1-5A3 (Sheehan et al., 2006). When 0.5 mg of anti-Ifnar1 mAb was administered one day before infection, POWV Spooner resulted in 100% lethality, with a mean time to death of 9.7 days (Figure 1D). Whereas POWV Spooner-infected WT mice typically displayed 15%–20% body weight loss, infected mice treated with anti-Ifnar1 mAb sustained greater weight loss of ~30% (Figure 1E). Most POWV Spooner-infected WT mice (70%–85%) displayed ruffled fur, hunched posture, and lethargy, with a minority developing limb paralysis (Figure 1F). In comparison, anti-Ifnar1 mAb-treated, POWV Spooner-infected mice uniformly displayed signs of morbidity before death.

**An mRNA Vaccine against POWV Induces High Levels of Neutralizing Antibody in Mice**

Having developed lethal challenge models in older mice, we engineered a LNP-encapsulated modified mRNA vaccine against POWV that was based on a prM-E construct developed for ZIKV (Richner et al., 2017a, 2017b). We designed a base-modified mRNA encoding the prM and E genes of POWV Spooner that was preceded by the prM signal sequence of POWV (POWVsig).
Figure 3. POWV mRNA LNP Vaccines Induce Protective Immunity against Lineage I and II POWV Strains

(A–F) C57BL/6 mice receiving two doses of POWVsig or JEVsig vaccines or a placebo were challenged 4 weeks after the second dose with $10^2$ FFU of (A–C) POWV lineage II strain Spooner (following anti-Ifnar1 mAb treatment) (n = 10 per group) or (D–F) POWV lineage I strain LB (n = 10 for JEVsig and placebo; n = 9 for POWVsig).

(G–I) Serum samples were collected from mice that received two doses of POWVsig or a placebo and passively transferred to naive C57BL/6 mice one day before challenge with $10^2$ FFU POWV LB (n = 9 per group). Mice received a dose of 3 or 10 μL of vaccine immune serum or 10 μL of placebo serum.

Mice were monitored for mortality (A, D, and G) for 21 days following viral challenge. Statistical significance was determined by the log rank test with a Bonferroni correction (**p < 0.001; ****p < 0.0001). Mean weight change (B, E, and H) post-viral challenge is shown. Error bars represent SEM. Statistical significance was determined by the log rank test with a Bonferroni correction (**p < 0.001; ****p < 0.0001).
signal sequence of JEV (JEVsig); the latter heterologous JEV signal sequence was tested because for some flaviviruses, it results in enhanced secretion of SVPs (Davis et al., 2001; Dowd et al., 2016). Six-week-old WT C57BL/6 mice were immunized with 10 μg of POWVsig, JEVsig, or placebo LNPs by intramuscular inoculation, followed by a second 10 μg booster dose 28 days later (Figure 2A). Serum was collected preboost on day 27 and post-boost on day 42, and neutralizing activity was assessed by reporter virus particle (RVP) assay using the C-prM-E proteins of the POWV lineage II strain P0375 and Raji-SIGNR cells (Mukherjee et al., 2014). RVP technology has been used extensively in the preclinical and clinical evaluation of flavivirus vaccine candidates (Dowd et al., 2016; Emanuel et al., 2018; Gaudinski et al., 2018; Pardi et al., 2017; Richner et al., 2017a). Following the first dose, the reciprocal mean titers that reduced RVP infection by 50% (50% maximal effective inhibitory concentration [EC50]) values were 13,683 ± 2,671 (n = 20) and 9,476 ± 1,271 (n = 20) for POWVsig and JEVsig, respectively, and were not statistically different between the two formulations (p > 0.9). Neutralization titers were boosted approximately 15-fold following the second dose for both formulations, with EC50 values of 200,402 ± 20,414 (n = 20) for POWVsig and 225,380 ± 21,112 (n = 20) for JEVsig. Despite the high EC50 values after the first dose, a neutralization-resistant fraction was observed for both formulations. However, this fraction was reduced following the booster dose from 20% to 7% (p < 0.0001 for both vaccines) (Figures 2C–2H).

mRNA Vaccines Protect against Lethal Challenge with Lineage I and II POWV Strains

Following the two-dose vaccination schedule, mice were challenged via subcutaneous inoculation with 10^2 FFU of POWV Spooner or POWV LB at 28 days post-boost (Figure 2A).

Figure 4. Single Dose of an mRNA LNP Vaccine Induces Protective Immunity against POWV Challenge

C57BL/6 mice receiving one dose of the POWVsig mRNA vaccine or a placebo vaccine were challenged 29 days later with 10^7 FFU of POWV Spooner (following anti-Ifnar1 mAb treatment) (n = 10 per group). (A) Mice were monitored for mortality for 21 days after viral challenge. Statistical significance was determined by log rank test (**p < 0.001; ***p < 0.0001). (B) Mean weight change after virus challenge is shown. Error bars represent SEM. Statistical significance was determined using an ANOVA with Sidak’s multiple comparisons test (**p < 0.001). (C) Serum was collected at 2 dpi and measured for viremia by qRT-PCR. Median viral titers are shown. Statistical significance was determined by Mann-Whitney test (**p < 0.001). (D–F) Serum was collected at 2 and 21 days post-challenge and assayed for neutralization activity by RVP assay. (D) Neutralization titers are shown. Bars indicate median values. Statistical significance was determined by paired t test. (E and F) Representative dose response curves are shown of sera collective at day 2 (E) and day 21 (F) post-challenge. Error bars represent ± SEM from two technical replicates. Serum samples were collected over two independent experiments and assayed once each for neutralization potency.
POWV Spooner-challenged mice were treated one day before infection with 0.5 mg anti-Ifnar1 mAb to achieve high mortality rates in placebo-treated mice. Challenged mice were monitored for survival and weight loss for 21 days, and serum samples were collected two days post-challenge and assayed for viremia. Following POWV Spooner challenge in anti-Ifnar1 mAb-treated mice, and as expected, 100% of placebo-vaccinated mice succumbed to infection. In comparison, all POWVsig mRNA-vaccinated mice survived the challenge (Figure 3A). Furthermore, both POWVsig- and JEVsig-vaccinated mice maintained body weight, whereas placebo-vaccinated mice lost 30%–40% of their weight (Figure 3B). Consistent with these data, high levels of viremia were measured in placebo-vaccinated mice, but not in POWVsig- and JEVsig-vaccinated mice (Figure 3C). Similar results were observed following POWV LB challenge in the absence of anti-Ifnar1 mAb treatment. Whereas 80% of placebo-vaccinated mice succumbed following LB infection, 100% of POWVsig- and JEVsig-vaccinated mice survived infection (Figure 3D). Placebo-vaccinated mice lost between 20% and 40% of body weight, whereas POWVsig- and JEVsig-vaccinated mice maintained weight following virus challenge (Figure 3E). In addition, viremia was undetectable in POWVsig- or JEVsig-vaccinated mice but present in placebo-vaccinated mice (Figure 3F). Thus, both mRNA vaccine formulations protect against lethal POWV challenge with strains from both lineages.

### Passive Transfer of Serum from POWV mRNA-Vaccinated Animals Protects against Lethal POWV Challenge

To assess the role of the humoral immune response in mediating protection from POWV challenge, we passively transferred serum from POWVsig-vaccinated (post-boost, day 42) or placebo-treated mice to naïve C57BL/6 mice one day before inoculation with 10^5 FFU of POWV LB. Whereas 8 of 9 (89%) mice that received 10 μL of serum from placebo-treated mice succumbed to POWV LB challenge, 3 of 9 (33%) and 0 of 9 (0%) mice that received 3 and 10 μL of serum, respectively, from POWVsig-vaccinated mice succumbed to viral challenge (Figure 3G). Furthermore, the 67% and 100% of mice that survived viral challenge following passive transfer of 3 and 10 μL of POWVsig serum, respectively, exhibited no weight loss following viral challenge, whereas all mice receiving serum from placebo-treated mice lost between 15% and 30% of their body weight. Passive transfer of serum from vaccinated mice resulted in significant reductions in viremia at 2 dpi: mice receiving 3 μL of POWVsig serum had more than a 500-fold reduction (p < 0.05) in viremia following challenge compared to mice receiving serum from placebo-treated mice, and viremia was undetectable in mice that received 10 μL of POWVsig serum. These data indicate that the humoral immune response to POWVsig vaccination is sufficient to protect mice from lethal POWV challenge.

### A Single Dose of POWV mRNA Vaccine Induces Protection

We next tested whether a single dose of the POWV mRNA vaccine was sufficient for protection. For this study, we immunized 10-week-old WT C57BL/6 mice with 10 μg of POWVsig or placebo vaccines. Twenty-eight days later, mice were treated with anti-Ifnar1 mAb and then challenged via subcutaneous inoculation with 10^5 FFU of POWV Spooner. As observed previously, 100% of placebo-immunized mice succumbed to infection and lost body weight (Figures 4A and 4B). In contrast, POWVsig-immunized mice uniformly survived challenge and maintained body weight. Furthermore, no viremia was detected in POWVsig-immunized mice at 2 dpi, compared to high levels in placebo-immunized mice (Figure 4C). Serum samples were collected on days 2 and 21 post-challenge for evaluation of neutralization titers. EC50 values were not significantly different between the two time points (p > 0.07) (Figure 4D), with most mice having less than a two-fold change in titer (Table 1), indicating that little or no boost in antibody response occurred following viral challenge in POWVsig-immunized mice. These data suggest that one dose of mRNA vaccine was sufficient to induce protective, if not sterilizing, immunity against POWV challenge.

### Cross-Neutralizing Activity of Serum from POWV mRNA-Vaccinated Mice against Other TBFVs

POWV shares 70%–78% amino acid identity of its E protein with other mammalian TBFVs and 55%–60% identity with the seabird TBFV clade (Figure 5A). To determine the ability of serum from POWV-vaccinated mice to inhibit other TBFVs, we tested sera from POWVsig- or JEVsig-vaccinated (two-dose) mice for their capacity to inhibit TBEV, LGTV, and GGYV (Figures 5B–5D; Figure S2). TBEV was chosen because it overlaps geographically with POWV in parts of far eastern Russia (Leonova et al., 2009, 2017) and has a large public health impact, infecting more than 10,000 people annually in Europe and Asia (Gritsun et al., 2003). LGTV was selected due to its relatedness to TBEV and prior use as a TBEV vaccine (Mandl et al., 1991). GGYV is one of the most divergent viruses of the mammalian

| EC50a Day 2 | EC50a Day 21 | Day 21/Day 2 Fold Change |
|-------------|-------------|-------------------------|
| 22213       | 32989       | 1.5                     |
| 13443       | 45702       | 3.4                     |
| 19565       | 30234       | 1.5                     |
| 32503       | 25243       | 0.8                     |
| 22913       | 19910       | 0.9                     |
| 11619       | 11871       | 1.0                     |
| 9921        | 22770       | 2.3                     |
| 30521       | 29327       | 1.0                     |
| 19043       | 30857       | 1.6                     |
| 18334       | 18706       | 1.0                     |
| 20008a      | 26761a      | 1.5b                    |

Table 1. Comparison of Neutralization Titers of Serum Collected on Day 2 or Day 21 Post-Challenge

Shown are the EC50 values of serum collected at day 2 or day 21 post-POWV challenge from mice receiving a single dose of POWVsig mRNA vaccine. The fold change of day 21 EC50/day 2 EC50 is shown for each sample. Serum samples were collected from two independent experiments.

*Mean

---

Cell Reports 25, 3382–3392, December 18, 2018 3387
group of TBFVs (Grard et al., 2007) and thus can demonstrate the breadth of cross-reactive response of the POWV vaccine sera. POWV shares about 77% amino acid identity in E protein sequence with LGTV and TBEV and 72% with GGYV. Most vaccine sera neutralized infection by RVPs bearing the E proteins of the other TBFVs, although some samples neutralized GGYV, whereas others did not (Figures 5B–5D). The variable neutralization of GGYV by POWV vaccine sera warrants further study but may be due to the greater sequence dissimilarity between the viruses (Figure 5A) and the resultant differential display of neutralizing epitopes. Sera from POWVsig-vaccinated mice exhibited cross-neutralizing activity with mean EC<sub>50</sub> values against TBEV, LGTV, and GGYV of 104 ± 21 (n = 15), 215 ± 112 (n = 13), and 113 ± 57 (n = 15), respectively. JEVsig induced similar cross-neutralizing titers against TBEV (82 ± 75, n = 15), LGTV (119 ± 92, n = 23), and GGYV (107 ± 60, n = 15).

**A POWV mRNA Vaccine Protects against LGTV Infection In Vivo**

Because both POWV mRNA vaccines showed a capacity for in vitro neutralization of other TBFVs, we tested the ability of the POWVsig vaccine to protect against LGTV challenge in vivo. We tested the efficacy of the POWVsig vaccine against LGTV, but not TBEV or GGYV due to the requirement of an A-BSL4 facility or lack of an existing challenge model, respectively. Following the two-dose vaccination schedule (Figure 2A), mice were challenged via subcutaneous inoculation with 10<sup>2</sup> FFU of LGTV at 28 days post-boost. Because LGTV is pathogenic in Ifnar1<sup>−/−</sup> mice, but not WT mice (Weber et al., 2014), we treated animals with 0.5 mg of anti-Ifnar1 mAb one day before virus challenge. Following LGTV challenge, 60% of placebo-treated mice lost 15% to 35% body weight, whereas only 7% of POWVsig-vaccinated mice lost more than 10% body weight and 87% of vaccinated mice maintained their weight (Figure 6A). POWVsig-vaccinated mice were fully protected from clinical disease, whereas ~50% of placebo-treated mice exhibited signs of paralysis, with one mouse succumbing to LGTV challenge (Figure 6B). POWVsig-vaccinated mice had significantly less viremia than placebo-treated mice at 2 dpi, with ~6,000-fold reduction in viral titer (p < 0.0001) (Figure 6C). POWVsig-vaccinated mice also had substantially less viral RNA in the spleen, brain, and spinal cord at 15 days post-LGTV challenge (p < 0.0001 for all comparisons) (Figure 5D). Thus, the POWVsig vaccine induces an immune response that can protect against heterologous challenge with LGTV.

**DISCUSSION**

The frequency of epidemics caused by emerging and reemerging viruses, such as ZIKV, chikungunya virus, Ebola virus, and Middle East respiratory syndrome coronavirus and the lack of preparedness for these public health crises highlight the need for the development of versatile vaccine platforms that can be rapidly manufactured and deployed against various viral threats. An advantage of the LNP-encapsulated modified mRNA platform is that it allows rapid development of vaccine candidates by insertion of the desired viral mRNA sequence into the coding region. In this study, we used the mRNA vaccine platform previously shown to be effective in mice against ZIKV (Pardi et al., 2018; Richner et al., 2017a) to develop a countermeasure against POWV, another emerging flavivirus (Hermance and Thangamani, 2017). Vaccination of mice with LNP-encapsulated mRNA-encoding POWV structural genes induced potent neutralizing antibody responses and protection against challenge by POWV strains from both lineages. Furthermore, one dose of the POWV mRNA vaccine was sufficient to induce robust immunity, because no viremia or significant anamnestic antibody response was observed following POWV challenge.
The antibody response induced by the POWV mRNA vaccines broadly neutralized infection of a panel of TBFVs that included LGTV, TBEV, and GGYV. These TBFVs differ from POWV E protein sequence by approximately 20% to 30%. The neutralization titers were lowest against GGYV, which is the more distantly related TBFV of those tested. Furthermore, the POWV mRNA vaccine protected mice from disease following LGTV challenge, indicating that this vaccine has inhibitory activity against multiple TBFV, although the durability of the cross-protective response warrants further testing.

Our results contrast with a prior study that observed little to no cross-reactivity of sera from TBEV-infected or TBEV-vaccinated humans against POWV (McAuley et al., 2017). This apparent disparity in results may have several reasons. The antibody repertoire produced in mice versus humans in response to TBFVs may be more cross-reactive, because mouse and human antibody specificities to TBEV immunization can be different (Jarmer et al., 2014). Notwithstanding these data, mouse immune ascites fluid raised against some TBFVs (TBEV, OHFV, and KFDV) was not neutralizing against POWV (McAuley et al., 2017). Furthermore, a separate study evaluating a TBEV vaccine in mice observed little cross-neutralization of POWV (a 1:8 antibody titer) and no cross-protection against POWV challenge in vivo (Chernokhaeva et al., 2016). It remains possible that there is a directionality to the cross-reactive response, such that POWV induces more cross-reactive antibodies than TBEV or other TBFVs due to differential display of conserved epitopes. Alternatively, the SVPs induced by the mRNA vaccine may display more cross-reactive epitopes than inactivated or fully infectious TBEV virions due to differences in the arrangement of E proteins on SVPs compared to virions (Kiermayr et al., 2009; Kuhn et al., 2015). Studies comparing the antibody repertoires induced by LNP-mRNA vaccines to those generated after live virus infections or inactivated virus vaccination could address these questions. In addition, the RVP-based assay we used to assess neutralization titers against TBEV may be more sensitive than the plaque-reduction neutralization test (PRNT) used by others. We observed increased sensitivity of the RVP-based neutralization assay compared to FRNT for POWV; however, the reciprocal result was true for LGTV in our study.

Another explanation for the difference in cross-neutralizing responses could be the timing of serum sampling. We evaluated the neutralization potency of sera collected 28 days post-vaccination, whereas McAuley and colleagues tested sera collected 3 to 204 months post-vaccination or 1.5 to 120 months post-infection (McAuley et al., 2017). Although a previous study showed the anti-ZIKV antibody responses to an LNP-encapsulated mRNA vaccine endure for at least five months post-vaccination (Pardi et al., 2018), the durability and breadth of the POWV LNP-mRNA antibody response
warrants further study. This may apply particularly to the cross-reactive antibody response, because anti-flavivirus antibody responses generated by long-lived plasma cells in the memory B cell compartment in the context of West Nile virus (WNV) infection had a more type-specific repertoire (Purtha et al., 2011). Moreover, previous studies with ZIKV and dengue virus (DENV) found the cross-neutralizing antibody response to flavivirus infections is greatest during the early-convalescent stage (<6 months) and then wanes over time (Collins et al., 2017; Montoya et al., 2018). Chernokhaeva and colleagues challenged mice with POWV four weeks following immunization with TBEV and observed no cross-protection (Chernokhaeva et al., 2016).

A neutralizing antibody response is an established correlate of protection following vaccination against several flaviviruses, including yellow fever virus, Japanese encephalitis virus, and TBEV (Belmusto-Worn et al., 2005; Heinz et al., 2007; Mason et al., 1973; Monath et al., 2002), and likely contributes to protection following immunization with the POWV LNP-mRNA vaccine. Passive transfer of serum from POWV LNP-mRNA-vaccinated mice was sufficient for protection against lethal POWV challenge. However, an LNP-mRNA ZIKV vaccine described by Pardi and colleagues induced strong, antigen-specific T cell responses, in addition to neutralizing antibodies (Pardi et al., 2018). Although we did not characterize the T cell response to the POWV mRNA-LNP vaccine, because insight into the immunodominance hierarchy and tetramer-specific reagents are lacking, if a similar such T cell response is generated, it could contribute to protection against POWV or LGTV challenge.

In summary, we show that the LNP-mRNA vaccine platform is readily adaptable for development of a vaccine against another flavivirus, POWV, with epidemic potential. This highlights the utility of this platform for development of vaccines against various flaviviruses, from both the mosquito-borne and the tick-borne nature, and points to the potential for optimizing adaptive immunity to flaviviruses, from both the mosquito-borne and the tick-borne nature.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes two figures and can be found with this article online at https://doi.org/10.1016/j.celrep.2018.11.082.

**ACKNOWLEDGMENTS**

This work was supported by grants from the NIH-NIAID (R01 AI073755), the intramural program of NIH-NIAID (to T.C.P.), and a research grant from Moderna. We also thank Brooke Bollman (Moderna) for aiding in the mRNA vaccine design and reviewing the manuscript.

**AUTHOR CONTRIBUTIONS**

Conceptualization, L.A.V., M.S.D., and S.H.; Methodology, L.A.V. and M.S.D.; Investigation, L.A.V. and B.M.F.; Resources, S.H., G.D.E., T.C.P., and B.M.F.; Supervision, M.S.D.; Writing – Original Draft, L.A.V. and M.S.D.; Writing – Review & Editing, all authors.

**DECLARATION OF INTERESTS**

M.S.D. is a consultant for Inbios and on the scientific advisory board of Moderna. S.H. is an employee of Moderna.

Received: October 5, 2018
Revised: November 15, 2018
Accepted: November 21, 2018
Published: December 18, 2018

**REFERENCES**

Aliota, M.T., Dupuis, A.P., 2nd, Wilczek, M.P., Peters, R.J., Ostfeld, R.S., and Kramer, L.D. (2014). The prevalence of zoonotic tick-borne pathogens in ixodes scapularis collected in the Hudson Valley, New York State. Vector Borne Zoonotic Dis. 14, 245–250.

Allison, S.L., Stadler, K., Mandi, C.W., Kunz, C., and Heinz, F.X. (1999). Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J. Virol. 69, 5816–5820.

Anderson, J.F., and Armstrong, P.M. (2012). Prevalence and genetic characterization of Powassan virus strains infecting Ixodes scapularis in Connecticut. Am. J. Trop. Med. Hyg. 87, 754–759.

Ansarah-Sobrinho, C., Nelson, S., Jost, C.A., Whitehead, S.S., and Pierson, T.C. (2008). Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology 371, 67–74.

Belmusto-Worn, V.E., Sanchez, J.L., McCarthy, K., Nichols, R., Bautista, C.T., Magill, A.J., Pastor-Cauna, G., Echevarria, C., Laguna-Torres, V.A., Samame, B.K., et al. (2005). Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am. J. Trop. Med. Hyg. 72, 189–197.

Brackney, D.E., Ofchissey, R.A., Fitzpatrick, K.A., Brown, I.K., and Ebel, G.D. (2008). Stable prevalence of Powassan virus in Ixodes scapularis in a northern Wisconsin focus. Am. J. Trop. Med. Hyg. 79, 971–973.

Brien, J.D., Lazear, H.M., and Diamond, M.S. (2013). Propagation, quantification, detection, and storage of West Nile virus. Curr. Protoc. Microbiol. 31, 15D.3.1–15D.3.18.

Campbell, M.S., and Pletnev, A.G. (2000). Infectious cDNA clones of Langat tick-borne flavivirus that differ from their parent in peripheral neurovirulence. Virology 269, 225–237.

Chernokhaeva, L.L., Rogova, Y.V., Vorovitch, M.F., Romanova, L.I., Kozlovskaia, I.I., Maikova, G.B., Khodolov, I.S., and Karganova, G.G. (2016). Protective immunity spectrum induced by immunization with a vaccine from the TBEV strain Sofjin. Vaccine 34, 2354–2361.

Collins, M.H., McGowan, E., Jadi, R., Young, E., Lopez, C.A., Baric, R.S., Lazear, H.M., and de Silva, A.M. (2017). Lack of durable cross-neutralizing...
antibodies against Zika virus from dengue virus infection. Emerg. Infect. Dis. 23, 773–781.

Davis, B.S., Chang, G.J., Cropp, B., Roehrig, J.T., Martin, D.A., Mitchell, C.J., Bowen, R., and Bunning, M.L. (2001). West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immuno sorbent assays. J. Virol. 75, 4040–4047.

Dowd, K.A., Ko, S.Y., Morabito, K.M., Yang, E.S., Pelc, R.S., DeMaso, C.R., Castillo, L.R., Abbinb, P., Boyd, M., Niyandamand, R., et al. (2016). Rapid development of a DNA vaccine for Zika virus. Science 354, 237–240.

Ebel, G.D. (2010). Update on Powassan virus: emergence of a North American tick-borne flavivirus. Annu. Rev. Entomol. 55, 95–110.

Ebel, G.D., Foppa, I., Spielman, A., and Telford, S.R., 2nd. (1999). A focus of tick-bite fever virus transmission in the northcentral United States. Emerg. Infect. Dis. 5, 570–574.

Ebel, G.D., Spielman, A., and Telford, S.R., 3rd. (2001). Phylogeny of North American Powassan virus. J. Gen. Virol. 82, 1657–1665.

Emanuel, J., Callison, J., Dowd, K.A., Pierson, T.C., Feldmann, H., and Marzi, A. (2018). A VSV-based Zika virus vaccine protects mice from lethal challenge. Sci. Rep. 8, 11043.

Gaudinski, M.R., Houser, K.V., Morabito, K.M., Hu, Z., Yamshchikov, G., Rothwell, R.S., Berkowitz, N., Mendoza, F., Saunders, J.G., Novik, L., et al.; VRC Gaudinski, M.R., Houser, K.V., Morabito, K.M., Hu, Z., Yamshchikov, G., Rothwell, R.S., Berkowitz, N., Mendoza, F., Saunders, J.G., Novik, L., et al.; VRC 21, 2016). Vaccination against tick-borne encephalitis. Vaccine 25, 7559–7567.

Grimaud, G., Berruti, N., Ebel, G.D., and Telford, S.R. (2008). Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 391, 552–562.

Grisits, T.S., Gaudinski, M.R., Houser, K.V., and Gould, E.A. (2003). Tick-borne encephalitis. Avantivir Res 57, 129–146.

Heinz, F.X., Allison, S.L., Stiasny, K., Schalich, J., Holzmann, H., Mandl, C.W., and Kunz, C. (1995). Recombinant and virion-derived soluble and particulate immuno genes for vaccination against tick-borne encephalitis. Vaccine 13, 1636–1642.

Heinz, F.X., Holzmann, H., Eslali, M., and Kundi, M. (2007). Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 25, 7559–7567.

Hermance, M.E., and Thangamani, S. (2015). Tick saliva enhances powassan virus transmission to the host, influencing its dissemination and the course of disease. J. Virol. 89, 7852–7860.

Hermance, M.E., and Thangamani, S. (2017). Powassan virus: an emerging arbovirus of public health concern in North America. Vector Borne Zoonotic Dis. 17, 453–482.

Holbrook, M.R., Aronson, J.F., Campbell, G.A., Jones, S., Feldmann, H., and Barrett, A.D. (2009). An animal model for the tickborne flavivirus—Omsk hemorrhagic fever virus. J. Infect. Dis. 199, 100–108.

Ishikawa, T., Yamanaka, A., and Konishi, E. (2014). A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 32, 1326–1337.

Jarmar, J., Zlatkovic, J., Tsuchinikas, G., Vratskikh, O., Straus, J., Aberle, J.H., Chmelik, V., Kundi, M., Stiasny, K., and Heinz, F.X. (2014). Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination. J. Virol. 88, 13845–13857.

Kiernayr, S., Stiasny, K., and Heinz, F.X. (2009). Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E. J. Virol. 83, 8482–8491.

Knox, K.K., Thomm, A.M., Harrington, Y.A., Ketter, E., Pattucci, J.M., and Carrigan, D.R. (2017). Powassan/deer tick virus and Borrelia burgdorferi infection in Wisconsin tick populations. Vector Borne Zoonotic Dis. 17, 463–466.

Konishi, E., and Fuji, A. (2002). Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20, 1058–1067.

Konishi, E., Pincus, S., Paoletti, E., Shope, R.E., Burrage, T., and Mason, P.W. (1992). Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/E and E proteins are protected from lethal JEV infection. Virology 188, 714–720.

Krow-Luca, E.R., Lindsey, N.P., Fischer, M., and Hills, S.L. (2018). Powassan virus disease in the United States, 2006–2016. Vector Borne Zoonotic Dis. 18, 286–290.

Kuhn, R.J., Dowd, K.A., Beth Post, C., and Pierson, T.C. (2019). Shake, rattle, and roll: impact of the dynamics of flavivirus particles on their interactions with the host. Virology 479–480, 509–517.

Leonova, G.N., Kondratov, I.G., Ternovoi, V.A., Romanova, E.V., Protopopova, E.V., Chausov, E.V., Pavlenko, E.V., Ryabchikova, E.I., Belikov, S.I., and Loktev, V.B. (2009). Characterization of Powassan viruses from Far Eastern Russia. Arch. Virol. 154, 811–820.

Leonova, G.N., Belikov, S.I., and Kondratov, I.G. (2017). Characteristics of far eastern strains of tick-borne encephalitis virus. Arch. Virol. 162, 2211–2218.

Mandi, C.W., Iacono-Connors, L., Wallner, G., Holzmann, H., Kunz, C., and Heinz, F.X. (1991). Sequence of the genes encoding the structural proteins of the low-virulence tick-borne flaviviruses Langat TP21 and Yelantsev. Virology 185, 891–895.

Mandi, C.W., Holzmann, H., Kunz, C., and Heinz, F.X. (1993). Complete genomic sequence of Powassan virus: evaluation of genetic elements in tick-borne versus mosquito-borne flaviviruses. Virology 194, 173–184.

Monath, T.P., Taura, T., Spertzel, R.O., and Ginn, R.K. (1973). Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 25, 539–544.

McAuley, A.J., Sawatsky, B., Ksiazek, T., Torres, M., Korva, M., Lotri, S., Avsic-Zupanc, T., van Messing, V., Holbrook, M.R., Freiberg, A.N., et al. (2017). Cross-neutralisation of viruses of the tick-borne encephalitis complex following tick-borne encephalitis vaccination and/or infection. NPJ Vaccines 2, 5.

McLean, D.M., and Donohue, W.L. (1959). Powassan virus: isolation of virus from a fatal case of encephalitis. Can. Med. Assoc. J. 80, 708–711.

Miera, L., Meade-White, K., Peterson, G., Scott, D., and Bloom, M.E. (2017). Modeling Powassan virus infection in Peromyscus leucopus, a natural host. PLoS Negl. Trop. Dis. 11, e005346.

Monath, T.P., Nichols, R., Archambault, W.T., Moore, L., Marchesani, R., Tian, J., Shope, R.E., Thomas, N., Schrader, R., Furby, D., and Bedford, P. (2002). Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am. J. Trop. Med. Hyg. 66, 533–541.

Montoya, M., Collins, M., Dejnirattisai, W., Kzetelnick, L., Puerta-Guardo, H., Jadi, R., Schildhauer, S., Supasa, P., Vasananawathan, S., Malais, P., et al. (2018). Longitudinal analysis of antibody cross-neutralization following Zika virus and Dengue virus infection in Asia and the Americas. J. Infect. Dis. 218, 536–545.

Mukherjee, S., Pierson, T.C., and Dowd, K.A. (2014). Pseudo-infectious reporter virus particles for measuring antibody-mediated neutralization and enhancement of dengue virus infection. Methods Mol. Biol. 1173, 75–97.

Pardi, N., Hogan, M.J., Pelc, R.S., Muramatsu, H., Andersen, H., DeMaso, C.R., Dowd, K.A., Sutherland, L.L., Searce, R.M., Parks, R., et al. (2017). Zika virus protection by a single low-dose nucleoside-modified mRNA vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Cell Reports 25, 3382–3392, December 18, 2018.
Platt, D.J., Smith, A.M., Arora, N., Diamond, M.S., Coyne, C.B., and Miner, J.J. (2018). Zika virus-related neurotropic flaviviruses infect human placental explants and cause fetal demise in mice. Sci. Transl. Med. 10, 426.

Purtha, W.E., Tedder, T.F., Johnson, S., Bhattacharya, D., and Diamond, M.S. (2011). Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J. Exp. Med. 208, 2599–2606.

Richner, J.M., Himansu, S., Dowd, K.A., Butler, S.L., Salazar, V., Fox, J.M., Julander, J.G., Tang, W.W., Shresta, S., Pierson, T.C., et al. (2017a). Modified mRNA vaccines protect against Zika virus infection. Cell 179, 176.

Richner, J.M., Jagger, B.W., Shan, C., Fontes, C.R., Dowd, K.A., Cao, B., Himansu, S., Caine, E.A., Nunes, B.T.D., Medeiros, D.B.A., et al. (2017b). Vaccine mediated protection against Zika virus-induced congenital disease. Cell 170, 273–283.

Santos, R.I., Hermance, M.E., Gelman, B.B., and Thangamani, S. (2016). Spinal cord ventral horns and lymphoid organ involvement in Powassan virus infection in a mouse model. Viruses 8, 8.

Sheehan, K.C., Lai, K.S., Dunn, G.P., Bruce, A.T., Diamond, M.S., Heutel, J.D., Dungo-Arthur, C., Carrero, J.A., White, J.M., Hertzog, P.J., and Schreiber, R.D. (2006). Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26, 804–819.

Thomas, L.A., Kennedy, R.C., and Eklund, C.M. (1960). Isolation of a virus closely related to Powassan virus from Dermacentor andersoni collected along North Cache la Poudre River, Colo. Proc. Soc. Exp. Biol. Med. 104, 355–359.

Wang, H., Siddharthan, V., Kesler, K.K., Hall, J.O., Motter, N.E., Julander, J.G., and Morrey, J.D. (2013). Fatal neurological respiratory insufficiency is common among viral encephalitides. J. Infect. Dis. 208, 573–583.

Weber, E., Finsterbusch, K., Lindquist, R., Nair, S., Lienenklaus, S., Gekara, N.O., Janik, D., Weiss, S., Kalinke, U., Överby, A.K., and Kröger, A. (2014). Type I interferon protects mice from fatal neurotropic infection with Langat virus by systemic and local antiviral responses. J. Virol. 88, 12202–12212.

Zhao, H., Fernandez, E., Dowd, K.A., Speer, S.D., Platt, D.J., Gorman, M.J., Govero, J., Nelson, C.A., Pierson, T.C., Diamond, M.S., and Fremont, D.H. (2016). Structural basis of Zika virus-specific antibody protection. Cell 166, 1016–1027.
STAR METHODS

KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Antibodies          |        |            |
| ZV-13               | Diamond laboratory | Zhao et al., 2016 |
| MAR1-5A3 (anti-IFNAR1) | Leinco | Cat#: I-401; RRID: AM_2737538 |
| Bacterial and Virus Strains |        |            |
| POWV strain LB      | Ebel laboratory | Mandl et al., 1993 |
| POWV-DTV strain Spooner | Ebel laboratory | Ebel et al., 1999 |
| LGTV strain E5      | Ebel laboratory | Campbell and Pletnev, 2000 |
| POWV-DTV strain MAS/12-#40 | Ebel laboratory | Brackney et al., 2008 |
| POWV-DTV strain FA5/12-#40 | Ebel laboratory | Brackney et al., 2008 |
| Experimental Models: Cell Lines |        |            |
| Vero                | ATCC   | CVCL_0069  |
| HEK293T             | ATCC   | CRL-3216   |
| Raji-DCSIGNR         | Pierson laboratory | N/A |
| Experimental Models: Organisms/Strains |        |            |
| C57BL/6J mice       | The Jackson Laboratory | 000664 |
| WNrepG/Z            | Pierson laboratory | N/A |
| POWV CprME (strain P0375) | Pierson laboratory | N/A |
| LGTV CprME strain TP21 | Pierson laboratory | N/A |
| TBEV CprME (strain Neudoerfl) | Diamond laboratory, this paper | N/A |
| GGVY CprME (strain Macquarie Island) | Diamond laboratory, this paper | N/A |
| Oligonucleotides    |        |            |
| POWV Spooner qPCR primer 5'- GCAGCACCAGTGGTGAATGT-3' | IDT | N/A |
| POWV Spooner qPCR primer 5'- CCACCACCTGGAACCAATT-3' | IDT | N/A |
| POWV Spooner qPCR probe 5'/56-FAM/ TCTCAGTG/G/Zen/ TTGGAGACACAGCGT/3/ABkF-3' | IDT | N/A |
| POWV LB qPCR primer 5'- GGCTGCAATGAAGACCAATT-3' | IDT | N/A |
| POWV LB qPCR primer 5'- CAGGACACATCTCCATGTC-3' | IDT | N/A |
| POWV LB qPCR probe 5'/56-FAM/TGGCATCGG/Zen/ AGAAATGTGATCCGC/3/ABkFQ/-3' | IDT | N/A |
| LGTV qPCR primer 5'- GGAACATGGCTTGGAGAAT-3' | IDT | N/A |
| LGTV qPCR primer 5'- TGTGTGTATGGTGGGTAG-3' | IDT | N/A |
| LGTV qPCR probe 5'/56-FAM/TGAGGTTAA/Zen/ CGTGCGCAGCTCAT/3/ABkF-3' | IDT | N/A |
| Other               |        |            |
| mRNA LNP vaccines (POWV and controls) | Moderna (current paper) | N/A |

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michael S. Diamond (diamond@wusm.wustl.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cells
Cell lines were maintained at 37°C in the presence of 5% CO2. HEK293T cells were passaged in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (FBS) (Omega Scientific) and 100 U/mL penicillin-streptomycin (PS)
(Invitrogen). Vero cells were passaged in DMEM supplemented with 5% FBS and 100 U/mL P/S. Raji B lymphoblast cells stably expressing the C-type lectin DC-SIGNR (Raji-DCSIGNR) were cultured in RPMI 1640 medium (Invitrogen) supplemented with 7% FBS and 100 U/mL P/S.

Mouse Studies
Experiments were approved and performed in accordance with Washington University Animal Studies Committee. C57BL/6J mice were purchased from Jackson Laboratories and housed in a pathogen-free animal facility at Washington University in St. Louis. Both male and female mice were vaccinated at 6 and 10 weeks of age (two dose studies) or 10 weeks of age (one dose study), and were infected with POWV or LGTV at 14 weeks of age, or 7 weeks where indicated.

METHOD DETAILS
Generation of modified mRNA and LNP
The mRNA was synthesized in vitro using DNA-dependent T7 RNA polymerase-mediated transcription where UTP was substituted with N1-methylpseudoUTP. A linearized DNA template was used, which incorporates 5′ and 3′ untranslated regions (UTRs) and includes a poly-A tail (5′-UTR: GGGAAAUAGAGAAGAGAGAGAAGAAAUAGAGGCCAC; and 3′-UTR: GCUGGAGCUCUGGUGGCUCUCUUCUGGAGGGCCUUCUUCCUCUUGAGCCGUACCCCCGUGGUCUUUGAAUAAGUGUCUGAGGCCGC). The final mRNA utilized a cap 1 structure modification to increase mRNA translation efficiency. Encoded signal sequences were from POWV prM (SGVDWTWTFLVMALMT) or JEV prM (MWLVSLAIVTACAGA) and the prM and E genes were derived from POWV Spooner.

LNP formulations were prepared by ethanol drop nanoprecipitation on a microfluidic mixer (Precision Nanosystems). Briefly, lipids were dissolved in ethanol at molar ratios of 50:10:38.5:1.5 (ionizable lipid: structural lipid: sterol: PEG-lipid) and mixed with mRNA in 50 mM citrate buffer, pH 4.0, at a ratio of 3:1 (aqueous:ethanol). Formulations were dialyzed against 20 mM Tris-Cl, pH 7.4, containing sucrose (8%) in dialysis cassettes for at least 18 h. Formulations were concentrated using Amicon Ultra Centrifugal Filters (EMD Millipore) and sterile filtered through 0.22-μm filters. All formulations were tested for particle size, RNA encapsulation, and endotoxin and were between 80 to 100 nm in size, with greater than 90% encapsulation and < 10 EU/ml of endotoxin.

Viruses
POWV lineage I strain LB (Mandl et al., 1993) was isolated originally from a human brain sample. POWV lineage II (DTV) strain Spooner was isolated originally from adult deer ticks (Ebel et al., 1999). LGTV strain E5 was derived from strain TP21 (Campbell and Pletnev, 2006). POWL LB, POWV Spooner, and LGTV were obtained from World Reference Center for Emerging Viruses and Arboviruses (R. Tesh and S. Weaver, University of Texas Medical Branch). POWV strains MA5/12-#40 and FA5/12-#40 were isolated from ticks collected in Wisconsin as described (Brackney et al., 2008). Virus was isolated by inoculating BHK-21 cells with 100 μl of the homogenate of POWV RNA positive ticks and harvesting virus supernatant when CPE was approximately 50%. Virus stocks were propagated on Vero cells and used at passage 3 (POWV LB and POWV Spooner) or passage 4 (LGTV). Viral titer was determined by focus-forming assay (FFA) on Vero cells as described previously (Brien et al., 2013) with the following modifications: FFA infections were fixed after 72 (POWV LB and POWV Spooner) or 48 (LGTV) h and stained with ZV-13, a flavivirus cross-reactive mouse mAb (Zhao et al., 2016).

Plasmids
The plasmid encoding a sub-genomic replicon of the WNV lineage II strain 956 that expresses GFP (WNVrepG/Z) has been reported (Ansarah-Sobrinho et al., 2008; Pierson et al., 2006). Plasmids that express the C-prM-E structural genes of POWV strain P0375 (GenBank accession number KU886216), TBEV strain Neudoerfl (GenBank accession number U27495), LGTV strain TP21 (GenBank accession number NC_003690), and GGYV strain Macquarie Island (GenBank: DQ235145) were cloned into the expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA). All plasmid propagation and cloning procedures were performed using Stbl2 bacteria grown at 30°C (Invitrogen, Carlsbad, CA).

Reporter virus particles
Reporter virus particles (RVPs) were produced by the genetic complementation of a DNA-launched, sub-genomic replicon with a C-prM-E expression plasmid, as described previously (Ansarah-Sobrinho et al., 2008; Pierson et al., 2006). Briefly, pre-plated HEK293T cells were co-transfected with WNVrepG/Z, a WNV replicon expressing a GFP reporter gene, and the C-prM-E expression plasmids described above using FugeneHD (Promega) in accordance with the manufacturer’s instructions. Transfected cells were incubated at 37°C, and supernatant was harvested at 48 h post-transfection, filtered using a 0.22 μm syringe filter, and stored at −80°C. The infectious titer of RVPs was assayed using Raji-DC-SIGNR cells, as described previously (Ansarah-Sobrinho et al., 2008; Pierson et al., 2006).

Neutralization assays
(a) RVP neutralization assays were performed as described (Mukherjee et al., 2014). Briefly, RVP stocks were diluted and incubated with serial dilutions of serum for 1 h at 37°C prior to the addition of Raji-DCSIGNR cells. Infections were carried out at 37°C for 48 h,
and infectivity was scored as the percentage of GFP-expressing cells determined by flow cytometry. (b) Focus-reduction neutralization test (FRNT) experiments were performed as described for other flaviviruses (Richner et al., 2017a). Briefly, serial dilutions of serum were incubated with 200 FFU of POWV Spooner for 1 h at 37°C. Serum/virus mixtures were added to Vero cell monolayers and incubated for 1 h at 37°C prior to the addition of 1% (w/v) methycellulose in MEM. FRNT experiments proceeded as described for FFA experiments above. For both RVP neutralization assays and FRNT, antibody-dose response curves were analyzed using non-linear regression analysis (with a variable slope) (GraphPad Software). Data are expressed as the serum dilution required to reduce infection by half (EC50) or, where indicated, by 90% (EC90). To obtain EC50 values when a resistant fraction was present, the bottom of the curve was constrained to zero.

**Mouse experiments**

Immunizations with the LNP mRNA vaccines were administered via intramuscular injection in a 50 μL volume. For passive transfer studies, serum was diluted in PBS and administered to mice via intraperitoneal injection in a 100 μL total volume; mice received a dose of 3 μL or 10 μL of serum from POWV_sag-vaccinated mice or 10 μL of serum from placebo-treated mice. Viral infections with POWV or LGTV were performed via subcutaneous inoculation in the footpad with 10^2 FFU of virus. For LGTV and POWV Spooner challenge, 0.5 mg of anti-Ifnar1 blocking mAb MAR1-5A3 (Sheehan et al., 2006) was administered one day prior to infection via intraperitoneal injection. Animals were monitored for mortality, weight loss, and clinical score. To evaluate clinical disease following POWV infection, mice were assigned to one of the following categories each day: (A) no disease, (B) ruffled fur, (C) ruffled fur with hunched posture, (D) lethargy or decreased scurrying activity, (E) sick with slow to no movement, or (F) moribund or dead; moribund mice were euthanized. To evaluate clinical disease following LGTV challenge, cages were blinded and mice were assigned to one of the following categories each day: (A) no disease, (B) partial hindlimb paralysis, (C) complete paralysis of one hindlimb, (D) complete paralysis of both hindlimbs, or (E) moribund or dead; moribund mice were euthanized.

**Measurement of viral burden**

On indicated days post-infection, mice were sacrificed and organs were collected following extensive perfusion with PBS. Organs were weighed and homogenized using a MagNA Lyser (Roche). Viral RNA from homogenized organs or serum was isolated using the MagMAX Viral RNA Isolation Kit (ThermoFisher) and measured by TaqMan one-step quantitative reverse-transcription PCR (RT-qPCR) on an ABI 7500 Fast Instrument. Viral RNA levels are expressed on a log10 scale as viral RNA equivalents per gram or milliliter after comparison with a standard curve produced using serial 10-fold dilutions of viral RNA from known quantities of infectious virus in order to estimate viral burden. POWV Spooner primers, which have been described (Platt et al., 2018), were 5’-GCAGGACCATAGGTAGAATGT-3’, 5’-CCACCCACTGAACCAAAGT-3’, and probe 5’-/56-FAM/TCTCAGTGG/Zen/TTGGAGAACACGCAT/3IABkFQ-3’. POWV LB primers were 5’-GGCTGCAAATGAGACCAATTC-3’, 5’-CAGCGACACATCTCCATAGTC-3’, and probe 5’-/56-FAM/TGGCATCCG/Zen/AGAAAGTGATCCTGC/3IABkF-3’. LGTV primers were 5’-GGAACTAGGCCTTGCAGAAT-3’, 5’-TGTTCTCCATTGTCGGGTTAG-3’, and probe 5’-/56-FAM/TGAGGTTAA/Zen/CGTGGCCATGCTCAT/3IABkF-3’.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Statistical analyses were performed using Prism software Version 7.0 for Mac OS X (GraphPad Software). Log EC50 or Log EC90 values were compared by one-way ANOVA followed by Tukey’s multiple comparisons test. For survival analysis, Kaplan-Meier curves were plotted and analyzed by the log rank test with a Bonferroni correction for multiple comparisons. Weight loss experiments were compared by an ANOVA followed by Dunn’s multiple comparisons test to compare vaccine groups to the placebo group, or by Sidak’s multiple comparisons test when two groups were compared. Viremia and viral burden in tissues were compared by Mann-Whitney test when two groups were compared, or by Kruskal Wallis test followed by Dunn’s multiple comparisons test when more than two groups were compared.